Science Focus
Science Focus
Search
Biopharmaceuticals: large molecules, enormous potential
Researching, developing and manufacturing biopharmaceuticals is a highly complex and lengthy process, but it has enormous potential.
Interstitial lung disease in rheumatoid arthritis (RA-ILD)
Interstitial lung disease (ILD) is the most common type of lung condition associated with the systemic autoimmune disease rheumatoid arthritis (RA).
Central Nervous System Diseases
Central Nervous System Diseases
We’re looking for SAP developers to join our Global IT Department
Are you looking to take the next step in your career? Our global IT department has new SAP developer positions available!
Future of Diabetes
This video highlights the evolution of type 2 diabetes management
IL-11 inhibitor antibody clinical development launched
Boehringer Ingelheim has launched clinical development of its first-in-class IL-11 inhibitor antibody as a fibrotic disease treatment
Questions and Answers
Answers to common questions from both patients and health care professionals regarding Compassionate Use of experimental medications.
Experiences of living with cancer
We know from speaking with people living with cancer and their loved ones, that it’s often the small moments that can be the most significant.
Working with purpose
Colleagues tell their personal stories and what motivates them to contribute towards a better future for generations to come.
ArisGlobal acquires Boehringer Ingelheim technology
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
Semintra®
4mg/ml – Management of chronic kidney disease (CKD) in cats: for reduction of proteinuria associated with CKD in cats. 10mg/ml – Hypertension: indicated for the treatment (EU)/control (US) of feline systemic hypertension.
Top Employer: learning and development with an impact
David has been part of us for over 20 years. What has kept him is part of what makes us a Global Top Employer 2024: our learning and development offerings.
Metabolic Diseases
Metabolic Diseases
Patient Safety & Pharmacovigilance at Boehringer Ingelheim
Patients inspire us in our mission to lead the science that creates breakthrough therapies, so that our medicines transform patients’ lives.
Generalized pustular psoriasis: Unmet needs
Dr Clerisme-Beaty and Dr Strober MD, PhD discuss the impact of living with GPP including unseen challenges and future management.
Accelerating new cancer medicines in partnership with CBmed
Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients
Breakthrough in Artificial Intelligence ChatGPT
Is ChatGPT the AI revolution we were waiting for or only media hype? Experts from Boehringer Ingelheim take a close look.
Our Venture Fund on the search for groundbreaking trends
The Boehringer Ingelheim Venture Fund acquires minority stakes in biotech start-ups, and even supports the majority before and during their founding.
Physical Wellbeing
Resources and videos related to physical wellbeing whilst living with cancer.
Zoonotic diseases things you should know
Zoonotic diseases can be transmitted between animals and humans. They are more common than you may think – and they are on the rise. Find out how this affects you.
Data science, agile working, UX design: our evolving IT careers
Meet our IT colleagues working in the fields of user experience, data science and agile development
Top Employer: learning and development with an impact
David has been part of us for over 20 years. What has kept him is part of what makes us a Global Top Employer 2024: our learning and development offerings.
Advancing health equity for rural doctors in Mexico
Our virtual sales team helps doctors stay informed through digital education about the latest treatments, regardless of their location
Digital innovation: „We change the way labs work“
QUDA – an in-house software – changes the way labs work. It increases our quality assurance and our drug saftey.